Key result
Cyclosporine administration in the aviremic stage of coxsackievirus B3 myocarditis resulted in lower survival (68% vs 96%, p<0.05) and failed to change myocardial lymphocyte subset distribution.
Why the study?
Does cyclosporine improve survival or alter myocardial lymphocyte subsets in the aviremic stage of Coxsackievirus B3 myocarditis in mice?
Population
2-week-old BALB/c mice inoculated with 3 x 10^2 plaque-forming units of Coxsackievirus B3
Comparison
Cyclosporine 25 mg/kg/day administered… vs Untreated infected controls
Design
Preclinical
Follow-up
Up to day 31 (experiment 1) or day 51 (experiment 2)
Authors
Loading...
May worsen outcomes in aviremic CVB3 myocarditis; hypothesis-generating for timing and lymphocyte effects in viral models.
Does cyclosporine improve survival or alter myocardial lymphocyte subsets in the aviremic stage of Coxsackievirus B3 myocarditis in mice?
Absolute Event Rate: 68% vs 96%
p-value: p=<0.05
Cyclosporine does not provide beneficial effects in the aviremic stage of Coxsackievirus B3 myocarditis and may increase mortality, likely due to a lack of cyclosporine-sensitive cells in the myocardium.
Kishimoto et al. (1989) studied Coxsackievirus B3 myocarditis (n=118). Cyclosporine vs. Infected controls (untreated) was evaluated on Survival rate (Experiment 1) (p=<0.05). Cyclosporine administration in the aviremic stage of coxsackievirus B3 myocarditis resulted in lower survival (68% vs 96%, p<0.05) and failed to change myocardial lymphocyte subset distribution.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: